As is often the case, a failure in science, in reality, did not invalidate a strong GLP-1 hypothesis, rather it improves, or refines, it for follow up investigations
If patients do not tolerate the 25 mg once-daily maintenance dosage, consider switching to Wegovy pen 1.7 mg once weekly
Skin aging In a 2018 review, the authors detailed multiple positive studies and trials on the use of GHK-Cu for signs of skin aging
[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
The best-known human studies involving CJC-1295 focused specifically on the DAC version